Alterity Therapeutics Limited Stock Nasdaq
Stocks
ATHE
US02155X2053
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.690 USD | -0.21% |
|
-7.77% | +52.27% |
| Market Cap | 87.19M 76.68M 71.23M 65.52M 123M 8.44B 125M 852M 332M 4.12B 327M 320M 14.29B | P/E 2026 * |
-0.34x | P/E 2027 * | -0.33x |
|---|---|---|---|---|---|
| Enterprise Value | 42M 36.94M 34.31M 31.56M 59.18M 4.07B 60.24M 410M 160M 1.98B 158M 154M 6.88B | EV / Sales 2026 * |
16.4x | EV / Sales 2027 * | 38.6x |
| Free-Float |
91.76% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alterity Therapeutics Limited
| 1 day | -0.21% | ||
| 1 week | -7.77% | ||
| Current month | -12.66% | ||
| 1 month | -5.44% | ||
| 3 months | +7.32% | ||
| 6 months | +32.11% | ||
| Current year | +52.27% |
| 1 week | 4.6 |  | 5 |
| 1 month | 4.6 | | 5.89 |
| Current year | 3.02 | | 5.89 |
| 1 year | 2.66 | | 7 |
| 3 years | 1 | | 7 |
| 5 years | 1 | | 18.2 |
| 10 years | 1 | | 66.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
Abby Niven
DFI | Director of Finance/CFO | - | 30/09/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.21% | -7.77% | - | - | 85.99M | |
| +1.08% | -5.74% | -4.98% | +10.45% | 46.06B | |
| +3.13% | +5.34% | +402.93% | +605.08% | 38.91B | |
| +2.14% | +2.95% | +10.83% | +65.45% | 35.57B | |
| +4.43% | -1.51% | +6.73% | -9.17% | 33.13B | |
| +1.23% | -2.05% | +0.56% | +30.76% | 26.42B | |
| +0.29% | -2.75% | - | - | 16.61B | |
| +14.71% | +12.62% | +38.50% | +146.99% | 15.08B | |
| -6.32% | -4.86% | +4.36% | +8.22% | 14.08B | |
| +1.82% | +0.19% | +1.45% | -30.74% | 12.81B | |
| Average | +2.08% | -0.43% | +57.55% | +103.38% | 26.52B | |
| Weighted average by Cap. | +2.22% | -1.28% | +75.35% | +129.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.57M 2.26M 2.1M 1.93M 3.62M 249M 3.68M 25.09M 9.79M 121M 9.64M 9.43M 421M | 1.2M 1.06M 981K 902K 1.69M 116M 1.72M 11.73M 4.57M 56.69M 4.51M 4.41M 197M |
| Net income | -14.64M -12.88M -11.96M -11M -20.64M -1.42B -21.01M -143M -55.8M -692M -54.97M -53.79M -2.4B | -29.66M -26.09M -24.23M -22.29M -41.8M -2.87B -42.55M -290M -113M -1.4B -111M -109M -4.86B |
| Net Debt | -45.19M -39.74M -36.92M -33.96M -63.68M -4.38B -64.82M -442M -172M -2.13B -170M -166M -7.41B | -40.88M -35.96M -33.4M -30.72M -57.61M -3.96B -58.64M -399M -156M -1.93B -153M -150M -6.7B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/07/26 | USD 4.690 | -0.21% | 9,552 |
| 22/07/26 | USD 4.700 | -5.62% | 11,650 |
| 21/07/26 | USD 4.980 | +5.06% | 2,860 |
| 20/07/26 | USD 4.740 | -4.82% | 44,197 |
| 17/07/26 | USD 4.980 | -2.06% | 9,374 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
- ATHE Stock
Select your edition
All financial news and data tailored to specific country editions
